The incidence of genital warts in Australian women prior to the national vaccination program.
The quadrivalent human papillomavirus (HPV) vaccine currently being delivered to Australian women aged 12-26 years under the National HPV Vaccination Program promises to substantially reduce the incidence of genital warts. We review what is known about the burden of genital warts among Australian women. Incidence appears to peak among women aged 20-24 years, of whom 1.4% report genital warts in the previous year and who are hospitalised for treatment at a rate of 26 per 100,000. A surveillance system capable of documenting any decrease in the incidence of genital warts and recurrent respiratory papillomatosis after vaccination is urgently required.
Brotherton
Julia M L
JM
National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, The Children's Hospital at Westmead and the University of Sydney, Westmead, NSW 2145, Australia. jbrother@vcs.org.au
Heywood
Anita
A
Heley
Stella
S
D000293:Adolescent; D000328:Adult; D001315:Australia / Q000453:epidemiology; D003218:Condylomata Acuminata / Q000453:epidemiology* / Q000517:prevention & control*; D005260:Female; D007722:Health Knowledge, Attitudes, Practice; D006801:Humans; D015994:Incidence; D030361:Papillomavirus Infections / Q000453:epidemiology* / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000627:therapeutic use*; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000453:epidemiology / Q000517:prevention & control; D014611:Vaccination / Q000706:statistics & numerical data*; D016387:Women's Health; D055815:Young Adult
D053918:Papillomavirus Vaccines